**Nucleocapsid-His** 

Soluble SARS-CoV-2 nucleocapsid protein fused to a poly-histidine (6 x His) tag

Catalog code: his-sars2-n https://www.invivogen.com/sars2-nucleocapsid-proteins

For research use only, not for diagnostic or therapeutic use Version 20119-NJ

# **PRODUCT INFORMATION**

### Contents:

- 50 µg of lyophilized Nucleocapsid-His protein
- 1.5 ml endotoxin-free water

### Protein construction:

Full-length Nucleocapsid [M1-A419] with a poly-histidine tag in C-terminus  $% \left[ \left( A^{2}\right) \right] =0$ 

### Accession sequence: PODTC9

Species: SARS-CoV-2 (2019-nCoV); Wuhan-Hu-1 (D614) isolate

Tag: C-terminal poly-histidine (6 x His)

Total protein size: 430 a.a. (secreted form)

Molecular weight: ~52 kDa (SDS PAGE)

Purification: Ni2+ affinity chromatography

Purity: >95% (SDS-PAGE)

### Formulation:

 $0.2\ \mu\text{m}$  filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents

#### Storage:

- Product is shipped at room temperature. Store lyophilized product at -20 °C. Lyophilized product is stable for at least 1 year.

- Reconstituted protein is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

### Quality control:

- The size and purity of the protein has been confirmed by SDS-PAGE.

- Nucleocapsid-His has been functionally validated by ELISA using an Anti-SARS Nucleocapsid antibody.

- Absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue<sup>™</sup> TLR2 and TLR4 cellular assays.

### BACKGROUND

The SARS-CoV-2 Nucleocapsid (N) is an important structural protein that plays important roles in the viral life cycle including replication, transcription, and genome packaging<sup>1</sup>. The SARS-CoV-2 N features two important NTD and CTD functional domains in N-terminal and C-terminal, respectively<sup>1-6</sup>. NTD interacts with both the RNA genome and M proteins to form virion particles. The N protein interaction with the RNA forms the virus ribonucleoprotein core which is packed as a helical "beads-on-a-string" conformation. CTD allows RNA synthesis through binding of the replication-transcription complexes (RTCs), oligomerization of multiple N proteins through its dimerization domain, and genome incorporation into the new virion. N is a major immunogen of SARS-CoV-2. Indeed, elevated Anti-SARS-CoV-2 N IgG and IgM antibody titers have been reported in COVID-19 patients' sera<sup>7-9</sup>. These observations make SARS-CoV-2 N an attractive tool for early diagnosis<sup>7-9</sup> and a potential therapeutic drug-target<sup>3</sup>.

### PRODUCT DESCRIPTION

Nucleocapsid-His is a soluble SARS-CoV-2 fusion protein generated by fusing the full-length Nucleocapsid [M1-A419] to a C-terminal poly-histidine (6 x Histidine) tag with a 3 amino acid linker. This fusion protein has a molecular weight of ~52 kDa on a SDS PAGE gel. Nucleocapsid-His has been generated by recombinant DNA technology, produced in CHO cells, and purified by Ni2+ affinity chromatography.

### **APPLICATIONS**

• Vaccination studies: using combinations of Nucleocapsid protein antigens and adjuvants.

• Antibody screening: finding anti-Nucleocaspid antibodies in COVID-19 patients' sera..

• Inhibitor screening: finding small molecules able to block the SARS-CoV-2 nucleocapsid interaction with replication-transcrption complexes (RTCs).

# METHODS

### Nucleocapsid-His resuspension (100 µg/ml)

<u>Note:</u> Ensure you see the lyophilized pellet before resuspension.

- Add 500 µl of endotoxin-free water to the vial and gently pipette until completely resuspended.

- Prepare aliquots and store at -20 °C or 4°C.





## **PROTEIN SEQUENCE**

M E I K V L F A L I C I A V A E A L E M S D N G P Q N Q R N A P R I T F G G P S D S T G S N Q N G E R S G A R S K Q R R P Q G L P N N T A S W F T A L T Q H G K E D L K F P R G Q G V P I N T N S S P D D Q I G Y Y R R A T R R I R G G D G K M K D L S P R W Y F Y Y L G T G P E A G L P Y G A N K D G I I W V A T E G A L N T P K D H I G T R N P A N N A A I V L Q L P Q G T T L P K G F Y A E G S R G G S Q A S S R S S S R S R N S S R N S T P G S S R G T S P A R M A G N G G D A A L A L L L L D R L N Q L E S K M S G K G Q Q Q Q G Q T V T K K S A A E A S K K P R Q K R T A T K A Y N V T Q A F G R R G P E Q T Q G N F G D Q E L I R Q G T D Y K H W P Q I A Q F A P S A S A F F G M S R I G M E V T P S G T W L T Y T G A I K L D D K D P N F K D Q V I L L N K H I D A Y K T F P P T E P K K D K K K K K A D E T Q A L P Q R Q K K Q Q T V T L L P A A D L D D F S K Q L Q Q S M S S A D S T Q A G S G H H H H H

Green: signal sequence Purple: stabilizing amino acid sequence Blue: Nucleocapsid sequence Black: tri-amino acid short linker Red: 6 x Histidine

# REFERENCES

1. Mu, J. et al., 2020. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells. Sci China Life Sci 63, 1-4. 2. Chang C. et al., 2006. Modular organization of SARS coronavirus nucleocapsid protein. J. Biom. Sci. 13:59-72. 3. Krokhin O. et al., 2003. Mass spectrometric characterization of proteins from the SARS virus. Mol. & Cell. Prot. 2:346-356. 4. Cubuk, J. et al., 2020. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. bioRxiv. doi:10.1101/2020.06.17.158121. 5. Kang, S. et al., 2020. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. doi:10.1016/j. apsb.2020.04.009. 6. Khan, M.T. et al., 2020. SARS-CoV-2 nucleocapsid and Nsp3 binding: an in silico study. Arch Microbiol. doi: 10.1007/s02020-020-01998-6. 7. Liu, W. et al., 2020. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. J Clin Microbiol 58. 8. Guo L. et al., 2020. Frofiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases. 71(15):778-785. 9. To K. K-W. et al., 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases.

# **RELATED PRODUCTS**

Product		
Nucleocapsid-Fc	fc-sars2-n	
Spike-S1-Fc	fc-sars2-s1	
Spike-S1-His	his-sars2-s1	
Spike-RBD-Fc	fc-sars2-srbd	
Spike-RBD-His	his-sars2-srbd	

